series-a
Stage
1
Investors
About
FF Pharmaceuticals develops clinical-stage humanized anti-CD40 monoclonal antibodies intended as disease-modifying therapeutics for inflammatory and autoimmune diseases.
Explore FF Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.